KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities (2019 - 2024)

Aurinia Pharmaceuticals (AUPH) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $10.8 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other Non-Current Liabilities rose 4.45% year-over-year to $10.8 million, compared with a TTM value of $10.8 million through Sep 2024, up 4.45%, and an annual FY2023 reading of $10.9 million, down 10.66% over the prior year.
  • Other Non-Current Liabilities was $10.8 million for Q3 2024 at Aurinia Pharmaceuticals, down from $12.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $17.9 million in Q1 2021 and bottomed at $8.7 million in Q2 2023.
  • Average Other Non-Current Liabilities over 4 years is $13.9 million, with a median of $14.1 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities tumbled 46.63% in 2023, then rose 4.45% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $16.0 million in 2021, then dropped by 23.75% to $12.2 million in 2022, then decreased by 10.66% to $10.9 million in 2023, then decreased by 0.92% to $10.8 million in 2024.
  • Business Quant data shows Other Non-Current Liabilities for AUPH at $10.8 million in Q3 2024, $12.3 million in Q1 2024, and $10.9 million in Q4 2023.